The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction.

Part A: Study description

Louise Paterson, Remy Flechais, Anna Murphy, Laurence Reed, Sanja Abbott, Venkataramana Boyapati, Rebecca Elliott, David Erritzoe, Karen D. Ersche, Yetunde Faluyi, Luca Faravelli, Emilio Fernandez-Egea, Nicola J. Kalk, Shankar Kuchibatla, John McGonigle, Antonio Metastasio, Inge Mick, Liam J. Nestor, Csaba Orban, Filippo Passetti & 10 others Eugenii A. Rabiner, Dana Smith, John Suckling, Roger Tait, Eleanor Taylor, Adam D. Waldman, Trevor W. Robbins, J. F. William Deakin, David J. Nutt, Anne Lingford-Hughes

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.
Original languageEnglish
Pages (from-to)943-960
Number of pages18
JournalJournal of Psychopharmacology
Volume29
Issue number9
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

vofopitant
aprepitant
Secondary Prevention
Biomedical Research
Opiate Alkaloids
Neuropharmacology
Pharmacology
Dopamine D3 Receptors
Neurokinin-1 Receptors
Recurrence
Naltrexone
Narcotic Antagonists
Impulsive Behavior
Reward
Cocaine
Pharmaceutical Preparations
Cross-Over Studies
Alcoholism
Substance-Related Disorders
Motivation

Cite this

Paterson, Louise ; Flechais, Remy ; Murphy, Anna ; Reed, Laurence ; Abbott, Sanja ; Boyapati, Venkataramana ; Elliott, Rebecca ; Erritzoe, David ; Ersche, Karen D. ; Faluyi, Yetunde ; Faravelli, Luca ; Fernandez-Egea, Emilio ; Kalk, Nicola J. ; Kuchibatla, Shankar ; McGonigle, John ; Metastasio, Antonio ; Mick, Inge ; Nestor, Liam J. ; Orban, Csaba ; Passetti, Filippo ; Rabiner, Eugenii A. ; Smith, Dana ; Suckling, John ; Tait, Roger ; Taylor, Eleanor ; Waldman, Adam D. ; Robbins, Trevor W. ; Deakin, J. F. William ; Nutt, David J. ; Lingford-Hughes, Anne. / The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. In: Journal of Psychopharmacology. 2015 ; Vol. 29, No. 9. pp. 943-960.
@article{71fc99ba694b47f4911dea65ee26e4ae,
title = "The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction.: Part A: Study description",
abstract = "Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.",
keywords = "Addiction, Functional magnetic resonance imaging, µ-Opioid receptor, Neurokinin 1 receptor, Dopamine D3 receptor",
author = "Louise Paterson and Remy Flechais and Anna Murphy and Laurence Reed and Sanja Abbott and Venkataramana Boyapati and Rebecca Elliott and David Erritzoe and Ersche, {Karen D.} and Yetunde Faluyi and Luca Faravelli and Emilio Fernandez-Egea and Kalk, {Nicola J.} and Shankar Kuchibatla and John McGonigle and Antonio Metastasio and Inge Mick and Nestor, {Liam J.} and Csaba Orban and Filippo Passetti and Rabiner, {Eugenii A.} and Dana Smith and John Suckling and Roger Tait and Eleanor Taylor and Waldman, {Adam D.} and Robbins, {Trevor W.} and Deakin, {J. F. William} and Nutt, {David J.} and Anne Lingford-Hughes",
note = "cited By 10",
year = "2015",
doi = "10.1177/0269881115596155",
language = "English",
volume = "29",
pages = "943--960",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "9",

}

Paterson, L, Flechais, R, Murphy, A, Reed, L, Abbott, S, Boyapati, V, Elliott, R, Erritzoe, D, Ersche, KD, Faluyi, Y, Faravelli, L, Fernandez-Egea, E, Kalk, NJ, Kuchibatla, S, McGonigle, J, Metastasio, A, Mick, I, Nestor, LJ, Orban, C, Passetti, F, Rabiner, EA, Smith, D, Suckling, J, Tait, R, Taylor, E, Waldman, AD, Robbins, TW, Deakin, JFW, Nutt, DJ & Lingford-Hughes, A 2015, 'The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description', Journal of Psychopharmacology, vol. 29, no. 9, pp. 943-960. https://doi.org/10.1177/0269881115596155

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. / Paterson, Louise; Flechais, Remy; Murphy, Anna; Reed, Laurence; Abbott, Sanja; Boyapati, Venkataramana; Elliott, Rebecca; Erritzoe, David; Ersche, Karen D.; Faluyi, Yetunde; Faravelli, Luca; Fernandez-Egea, Emilio; Kalk, Nicola J.; Kuchibatla, Shankar; McGonigle, John; Metastasio, Antonio; Mick, Inge; Nestor, Liam J.; Orban, Csaba; Passetti, Filippo; Rabiner, Eugenii A.; Smith, Dana; Suckling, John; Tait, Roger; Taylor, Eleanor; Waldman, Adam D.; Robbins, Trevor W.; Deakin, J. F. William; Nutt, David J.; Lingford-Hughes, Anne.

In: Journal of Psychopharmacology, Vol. 29, No. 9, 2015, p. 943-960.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction.

T2 - Part A: Study description

AU - Paterson, Louise

AU - Flechais, Remy

AU - Murphy, Anna

AU - Reed, Laurence

AU - Abbott, Sanja

AU - Boyapati, Venkataramana

AU - Elliott, Rebecca

AU - Erritzoe, David

AU - Ersche, Karen D.

AU - Faluyi, Yetunde

AU - Faravelli, Luca

AU - Fernandez-Egea, Emilio

AU - Kalk, Nicola J.

AU - Kuchibatla, Shankar

AU - McGonigle, John

AU - Metastasio, Antonio

AU - Mick, Inge

AU - Nestor, Liam J.

AU - Orban, Csaba

AU - Passetti, Filippo

AU - Rabiner, Eugenii A.

AU - Smith, Dana

AU - Suckling, John

AU - Tait, Roger

AU - Taylor, Eleanor

AU - Waldman, Adam D.

AU - Robbins, Trevor W.

AU - Deakin, J. F. William

AU - Nutt, David J.

AU - Lingford-Hughes, Anne

N1 - cited By 10

PY - 2015

Y1 - 2015

N2 - Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.

AB - Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.

KW - Addiction

KW - Functional magnetic resonance imaging

KW - µ-Opioid receptor

KW - Neurokinin 1 receptor

KW - Dopamine D3 receptor

UR - http://journals.sagepub.com/home/jop

U2 - 10.1177/0269881115596155

DO - 10.1177/0269881115596155

M3 - Article

VL - 29

SP - 943

EP - 960

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 9

ER -